Inappropriate	inappropriate	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
vigabatrin	vigabatrin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
typical	typical	O	O	O	O
absence	absence	O	O	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
vigabatrin	vigabatrin	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
contraindicated	contraindicated	O	O	O	O
in	in	O	O	O	O
typical	typical	O	O	O	O
absence	absence	O	O	OTHERS	I
seizures	seizures	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Of	of	O	O	O	O
18	18	O	O	O	O
consecutive	consecutive	O	O	O	O
referrals	referrals	O	O	O	O
of	of	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
resistant	resistant	O	O	O	O
typical	typical	O	O	O	O
absences	absences	O	O	O	O
only	only	O	O	O	O
,	,	O	O	O	O
eight	eight	O	O	O	O
were	were	O	O	O	O
erroneously	erroneously	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
either	either	O	O	O	O
as	as	O	O	O	O
monotherapy	monotherapy	O	O	O	O
or	or	O	O	O	O
as	as	O	O	O	O
an	an	O	O	O	O
add-on	add-on	O	O	O	O
.	.	O	O	O	O

Vigabatrin	vigabatrin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
also	also	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
two	two	O	O	O	O
children	children	O	O	O	O
.	.	O	O	O	O

Frequency	frequency	O	O	O	O
of	of	O	O	O	O
absences	absences	O	O	O	O
increased	increased	O	O	O	O
in	in	O	O	O	O
four	four	O	O	O	O
children	children	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
two	two	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
developed	developed	O	O	O	O
myoclonic	myoclonic	O	DISEASE	OTHERS	I
jerks	jerks	O	DISEASE	OTHERS	I
,	,	O	O	O	O
which	which	O	O	O	O
resolved	resolved	O	O	O	O
on	on	O	O	O	O
withdrawal	withdrawal	O	O	O	O
of	of	O	O	O	O
carbamazepine	carbamazepine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Absences	absences	O	O	O	O
were	were	O	O	O	O
aggravated	aggravated	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
cases	cases	O	O	O	O
where	where	O	O	O	O
vigabatrin	vigabatrin	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
added	added	O	O	O	O
on	on	O	O	O	O
to	to	O	O	O	O
concurrent	concurrent	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

Optimal	optimal	O	O	O	O
control	control	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
absences	absences	O	O	O	O
was	was	O	O	O	O
achieved	achieved	O	O	O	O
with	with	O	O	O	O
sodium	sodium	CHEMICALS	O	OTHERS	I
valproate	valproate	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
lamotrigine	lamotrigine	O	O	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
ethosuximide	ethosuximide	O	O	OTHERS	I
alone	alone	O	O	O	O
or	or	O	O	O	O
in	in	O	O	O	O
combination	combination	O	O	O	O
.	.	O	O	O	O

